ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
November 05, 2024 07:00 ET | ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
October 29, 2024 07:57 ET | ZyVersa Therapeutics
Obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
October 22, 2024 07:57 ET | ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
October 17, 2024 07:50 ET | ZyVersa Therapeutics
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
October 15, 2024 07:50 ET | ZyVersa Therapeutics
ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
October 07, 2024 07:55 ET | ZyVersa Therapeutics
ZyVersa Therapeutics forms new obesity, metabolic and inflammatory disease Scientific Advisory Board.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
August 09, 2024 16:40 ET | ZyVersa Therapeutics
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024.Obesity with related metabolic complications...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
August 07, 2024 07:50 ET | ZyVersa Therapeutics
Extracellular ASC has a crucial role in aggregation and deposition of amyloid A fibrils leading to associated chronic inflammatory conditions.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
July 29, 2024 07:45 ET | ZyVersa Therapeutics
Plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adults.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
July 25, 2024 07:57 ET | ZyVersa Therapeutics
WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...